Esperante Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Acousiaacousia.comJan 2024
Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing.
BiotechDigital HealthHealthtechMedical DevicesTübingen, DE
Hubert Löwenheim(Founder / Board Member)
Co-investorsBoehringer Ingelheim Venture FundKfWCreathor VenturesLBBW Venture Capital GmbH
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.